Wacker Biotech GmbH
Full-service provider for the microbial production of pharmaceutical proteins
Wacker Biotech GmbH, a wholly-owned WACKER subsidiary since January 2005, was developing therapeutic proteins for globally-active pharmaceutical and biotech companies as early as the 1980s. Commercial development and production followed from 1999 onwards. Our focus has always been on developing stable, highly efficient processes and technologies, which meet your requirements for cost-effective production and quality.
With the takeover of Halle-based Scil Proteins Production GmbH in 2014, we not only expanded our production capacity, but also acquired a number of patents, including one for the process known as refolding. The refolding of proteins that cannot be produced in an active form in bacterial cells is a key production stage, extending the range of services we offer.
Today the focus of the Halle site is on developing stable and highly efficient processes. The certified multifunctional facility in Halle supplies both mid-sized and globally-active pharmaceutical and biotech companies.
Site-Specific Facts & Figures
- Name: Wacker Biotech GmbH
- Site: Halle
- Employees: approx. 100
- Products: recombinant proteins (contract manufacturing), pharmaceutical actives for clinical testing and the commercial market
- The facility is certified in accordance with Good Manufacturing Practice (GMP) and complies with the requirements stipulated by the European and US drug-approval authorities (EMA and FDA, respectively)